Anti-Microbial Savior BioteQ , Ltd Return on Equity

Anti-Microbial Savior BioteQ , Ltd (6864.TWO) currently reports a ROE of -37.89%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Anti-Microbial Savior BioteQ , Ltd's ROE history and peer comparisons.

Anti-Microbial Savior BioteQ , Ltd's ROE of -37.89% is lower than the Healthcare sector average of 13.1%. That is roughly 389.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Anti-Microbial Savior BioteQ , Ltd's current -37.89% should be judged against Healthcare norms (sector average: 13.1%) and against 6864.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -37.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Anti-Microbial Savior BioteQ , Ltd, and consider following 6864.TWO for alerts when major investors trade the stock.

Anti-Microbial Savior BioteQ , Ltd is classified in the Healthcare sector. On ROE, it currently shows -37.89% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 6864.TWO with unrelated industries.